Top Markets
Coin of the day
Allena Pharmaceuticals, Inc. Allena Pharmaceuticals, Inc.

Allena Pharmaceuticals, Inc.

ALNAQ
Rangering i aksjer #42825
Operating as a biopharmaceutical firm, Allena Pharmaceuticals, Inc. focuses on... Operating as a biopharmaceutical firm, Allena Pharmaceuticals, Inc. focuses on unearthing, developing, and marketing oral enzyme therapies. These treatments are devised to assist patients in the United States afflicted by uncommon and serious metabolic as well as renal conditions. Central to its pipeline is ALLN-346, an innovative enzyme designed to degrade urate, targeting hyperuricemia and gout in individuals with advanced chronic kidney disease. The company, which commenced operations in 2011 and has its main office in Newton, Massachusetts, made headlines on September 2, 2022, by seeking voluntary reorganization under Chapter 11 in the U.S. Bankruptcy Court for the District of Delaware.
Aksjekurs
$0.000001
Sist synkronisert: 2023-12-13
Markedsverdi
$23.51
Endring (1 dag)
0.00%
Endring (1 år)
0.00%
Land
US
Handel Allena Pharmaceuticals, Inc. (ALNAQ)

Kategori

Driftsmargin for Allena Pharmaceuticals, Inc. (ALNAQ)
Driftsmargin per 2026 TTM: 0.00%
Ifølge Allena Pharmaceuticals, Inc. sine siste økonomiske rapporter og aksjekurs er selskapets nåværende driftsmargin (TTM) 0.00%. Ved slutten av 2026 hadde selskapet en driftsmargin på 0.00%.
Historikk for driftsmargin for Allena Pharmaceuticals, Inc. fra 2026 til 2026
Driftsmargin ved slutten av hvert år
År Driftsmargin Endre
Ikke nok data for de angitte datoene.
Driftsmargin for lignende selskaper eller konkurrenter
Selskap Driftsmargin Forskjell i driftsmargin Land
38.97% -
US
28.81% -
NL
0.00% -
CH
31.23% -
BE
0.00% -
KR
Hva er selskapets Driftsmargin?
Driftsmargin er en nøkkelindikator for å vurdere lønnsomheten til et selskap. Høyere Driftsmargins er vanligvis bedre, da de viser at selskapet kan selge sine produkter eller tjenester for mye mer enn produksjonskostnadene. Driftsmargin beregnes ved å dele selskapets inntjening med inntektene.